**Tigertriever® Revascularization Device Produced by Rapid Medical Ltd., an Affiliate Company of MicroPort® NeuroTech, Enters “Green Path”**

On May 27, 2020, the Tigertriever® Revascularization Device (RD) produced by Rapid Medical Ltd., an Israel-based affiliate company of MicroPort® NeuroTech Co., Ltd., was granted entry into the Special Review Procedure for Innovative Medical Devices (“Green Path”) with National Medical Products Administration of China (NMPA). Tigertriever® has become the 20th product of MicroPort® or its related companies that have entered the “Green Path” since 2015.

Mr. Roy Xie, President of MicroPort® NeuroTech, said, “Tigertriever® is a new generation stentriever. Currently, there are no devices with the same type of design mechanism as the Tigertriever® in the local market. The entry into the ‘Green Path’ is set to expedite its launch in China. Tigertriever® and the stentriever developed by MicroPort® NeuroTech constitute a dual stent strategy to make the product specifications more comprehensive, reach a wider range of lesion positions, and offer a more diversified pricing. The duo stent strategy aims to provide doctors and patients with more clinical options to create an integrated solution for neurovascular intervention.”
MicroPort® EP Obtains CE Mark for PathBuilder™ Steerable Introducer and Two Other Relevant Devices


PathBuilder™ Steerable Introducer, PathBuilder™ Transseptal Guiding Introducer and PathBuilder™ Transseptal Needle are the devices used in the radiofrequency ablation procedure on arrhythmia patients. They are used to build vascular access via femoral vein to guide ablation catheter or diagnostic/mapping catheter into the heart, including the left side of the heart through the interatrial septum.

The regulatory approvals for these three devices including PathBuilder™ Steerable Introducer will help MicroPort® EP provide the local doctors and patients with better options for guiding devices. Prior to this, MicroPort® EP’s Columbus™ 3D EP Navigation System, OptimAblate™ Cardiac RF Generator, OptimAblate™ Irrigation Pump and multiple catheters had also entered the European market. All the CE-marked devices of MicroPort® EP fuse into an integrated EP solution platform that combines active devices with non-active devices and devices with stand-alone equipment respectively. In addition, they have laid a solid groundwork for MicroPort® EP’s further expansion into the European Market.
MicroPort® EP Obtains Approvals for Catheter Devices and Supplies in Australia

On June 1, 2020, MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") obtained regulatory approvals for catheter devices and supplies from Therapeutic Goods Administration (TGA) of Australia, which marked the maiden call of the products of MicroPort® EP in the Australian market.

Severe arrhythmia is the main cause of sudden cardiac death. The radiofrequency ablation procedure is one of the major non-drug treatments of arrhythmia. The approved catheter devices and supplies are mainly used in the diagnosis and treatment of arrhythmia, which are FireMagic™ Cardiac RF Ablation Catheter, FireMagic™ 3D Irrigated Ablation Catheter, EasyLoop™ Circular Mapping Catheter, Columbus™ External Reference Patch, and FORLNK™ Cables.

The approvals signify that MicroPort® EP will provide local patients and doctors with a complete therapeutic solution featuring integrated electrophysiology. They have also laid a solid groundwork for MicroPort EP’s expansion into the Oceanian market.
MicroPort Firehawk® TARGET AC Clinical Study Three-year Results Announced at PCR E-course Affirms the Long-term Safety and Effectiveness of Firehawk®

One June 26, 2020, MicroPort Scientific Corporation ("MicroPort") announced today the three-year results from the TARGET AC study for its Firehawk Rapamycin Target Eluting Coronary Stent System ("Firehawk"). The long-term clinical data results from the TARGET AC study was presented for the first time during the PCR e-Course, hosted by the organizers of EuroPCR 2020, which was cancelled earlier this year due to the Covid-19 pandemic. The trial results were presented during the interviews and round table channel session by Professor William Wijns, the current chairman of PCR, Professor Alexandra Lansky, Yale University, and Professor Andreas Baumbach, the current chairman of The European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Results showed that at the two and three-year follow-up time point in the dual-antiplatelet (DAPT) treatment subgroup, the safety and effectiveness of the Firehawk stent was non-inferior to the Xience stent, one of the most extensively studied stent platforms.

The Firehawk stent by MicroPort is the world's first independently developed and commercially successful stent with a groove in the stent strut surface and a targeted release technology. The unique design of Firehawk where the amount of drug load used is greatly reduced (the drug load is 1/3 of similar products), and the absorbable polymer has the lowest polymer load compared with other biodegradable polymer drug-eluting stents in the world, combine the advantages of both drug eluting stents and bare metal stents. Through extensive, rigorous clinical study by the "gold standard" randomized controlled trial, the Firehawk continues to increase the body of clinical evidence for safety and efficacy, further establishing its status as an elite workhorse drug-eluting stent for worldwide use. In the future, MicroPort will continue to steadily advance its global series of clinical program plans, providing patients with safe and effective cardiovascular intervention therapies with the intent of continuously enriching global clinical research data.
MicroPort® Holds 2020 Annual General Meeting in Shanghai

MicroPort Scientific Corporation (the "Company", or "MicroPort") held the 2020 Annual General Meeting (the "Meeting") at its headquarters on June 18. Dr. Zhaohua Chang, Chairman of the Board of Directors, Executive Director and Chief Executive Officer of the Company, attended the Meeting at the headquarters. Mr. Norihiro Ashida, Mr. Hiroshi Shirafuji and Mr. Hongliang Yu, who are Non-executive Directors of the Company, joined in the Meeting by videoconference, as did Mr. Guoen Liu, Mr. Jonathan Chou and Mr. Chunyang Shao, who are Independent Non-executive Directors of the Company. Representation of KPMG, auditor of MicroPort, was also present at the Meeting. Dr. Zhaohua Chang presided over the Meeting.

In accordance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited and the Articles of Association, the shareholders and shareholder agents of MicroPort decided by poll on the 11 ordinary resolutions that had been set out in the notice of the Meeting. All the resolutions were passed with a majority of the shares with voting rights that were owned by the attending shareholders and shareholder agents.

At the Meeting, Dr. Zhaohua Chang, MicroPort® Chief Marketing Officer Mr. Bo Peng, Chief Financial Officer Mr. Martin Sun, Chief Operating Officer Ms. Glendy Wang, Chief Technology Officer Mr. Qiyi Luo, and Chief International Business Officer Mr. Jonathan Chen, as well as Mr. Lei Jiang, who is Senior Vice President, China Coronary Domestic Sales and Marketing, answered the questions from shareholders and shareholder agents.
**MicroPort® Announces Strategic Collaboration on Digital Subtraction Angiography System with Siemens Healthineers**

On June 24, 2020, led by MicroPort Scientific Corporation ("MicroPort®"), MicroImaging (Shenzhen) Medical Equipment Co., Ltd. ("MicroImaging"), a subsidiary of MicroPort®, has entered into a framework collaboration agreement with Siemens Healthineers. The two parties will jointly develop Chinese-made digital subtraction angiography systems ("DSAs").

DSAs are used for diagnosis and minimally invasive interventional treatment of the heart, brain and peripheral vessels. The devices visualize blood vessel lesions and assess stenosis. DSAs are widely considered the "gold standard" in angiography due to the clarity of imagery and high definition provided. Despite the importance and high regard of the device, statistics have shown that there are only three DSA units per one million people in China, and approximately 33 units per one million people in the US*. These statistics highlight the need for greater access to DSAs to enable healthcare professionals to offer optimum care to patients and demonstrate the potential for development of the DSA market in China.
MicroPort® Attends 14th Edition of Oriental Congress of Cardiology (OCC 2020)

From May 28 to June 3, the 14th edition of Oriental Congress of Cardiology (OCC 2020) was held via live streaming with 11 channels and 24 breakout forums, which drew tens of thousands of cardiologists. Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort") attended the congress and hosted the Firefighter™ Balloon satellite session and “How to Treat” case discussion. MicroPort also co-organized the Chest Pain Quality Control forum and PCI Complications session, as well as the production and viewing of a PCI-themed film the “Forgotten Time”.

On June 1, the Firefighter™ Balloon satellite session was held under the theme “Industrial Development Creates Progress in Technology”. The satellite session was hosted in the innovative form of dialogues between doctors and engineers, where the MicroPort Balloon and Catheter development team triggered sparks in mind with domestic PCI KOLs. They had discussions on the issues such as treatment of highly severe lesions and balloon choice strategies. All of them spoke highly of the outstanding performance of Firefighter™ Balloon demonstrated in highly tortuous and narrow complex lesions.
MicroPort® Wins the Title of Quality Benchmark in Shanghai for the Second Consecutive Year

Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) has won the title of 2019 Quality Benchmark in Shanghai, as the Shanghai Municipal Commission of Economy and Informatization announced 17 winners of the title on June 5. MicroPort® received the honor for the second consecutive year.

The selection of 2019 Quality Benchmark winners emphasized the companies with typical experience with respect to high-quality development, innovation in operational model, improvements in quality and efficiency, quality improvement by small- and medium-sized enterprises, and social responsibility. The Practice Experience of Implementing Comprehensive Risk Management and Control, which MicroPort submitted, presented in details on the risk management system established by integrating international advanced regulations. It also introduced the closed circuit risk management, which includes risk management system at center, internal and external prevention measures, and considerations of internal and external customer needs. MicroPort® has implemented comprehensive risk management for every of its products during the full-life cycle from the beginning of product concept to product retirement. MicroPort® has concluded a systematic methods from long-term risk management practice. MicroPort® has set up risk management process revolving around design, manufacturing, sales and after-sale services. Also, MicroPort® fully takes into consideration the six dimensions of people, machine, raw material, method, cycle, and test, so as to implement standardized and systematic risk management.
MicroPort® Lifesciences Awarded Shanghai Municipal Technological Invention Top Prize for Project of Development and Application of Key Technologies for Diagnosis and Treatment of Metabolic Diseases

At the 2019 Shanghai Municipal Science and Technology Award Congress held recently, Shanghai MicroPort Lifesciences Co., Ltd. ("MicroPort® Lifesciences"), a subsidiary of MicroPort Scientific Corporation ("MicroPort"), was awarded Shanghai Municipal Technological Invention Top Prize for Project of Development and Application of Key Technologies for Diagnosis and Treatment of Metabolic Diseases. The project was co-submitted by MicroPort® Lifesciences and Ruijin Hospital Affiliated to Medical School of Shanghai Jiao Tong University.

The Project of Development and Application of Key Technologies for Diagnosis and Treatment of Metabolic Diseases lasted eight years. It started from the clinical needs of doctors and patients to produce 12 items of invention of new technologies in a systematic manner. The project has significantly improved the prognosis of metabolic diseases and quality of life for the patients, which has provided a higher-quality therapeutic solution for the patients with metabolic diseases.
Investor Newsletter
Issue 06 2020

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & Vice President
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com